Drug Profile
Research programme: glucocorticoid-induced tumour necrosis factor receptor agonists - Apogenix
Alternative Names: GITR agonists - Apogenix; Glucocorticoid induced TNFR-related protein agonists - Apogenix; HERA GITR agonists; HERA GITR ligands; HERA-GITRL; Hexavalent GITR agonists - Apogenix; TNFRSF18 agonists - ApogenixLatest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Apogenix
- Class Antineoplastics; Recombinant fusion proteins
- Mechanism of Action TNFRSF18 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- No development reported Head and neck cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Head-and-neck-cancer in Germany
- 28 Oct 2021 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in Germany
- 28 Jan 2020 No recent reports of development identified for preclinical development in Solid-tumours in Germany